Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
Computer-aided detection, initially restricted to mammography, is entering the functional imaging arena. CTI Molecular Imaging is showcasing CAD technology during the RSNA meeting on its Reveal PET/CT scanners, as well as the Reveal MVS PET/CT workstation. Under a recently inked exclusive agreement with R2 Technology, CTI has begun offering the first commercially available CAD system for multidetector CT examinations of the chest.
The Reveal PET/CT system merges PET and CT technologies to generate functional and anatomical data in a single scan, which improves the localization of metabolic hot spots for cancer staging.
FDG, the active metabolite of PET scanning, accumulates not only in disease sites, but also in areas of inflammation and infection. The addition of CAD to the Reveal PET/CT system helps decipher inflammatory isotope uptake from metabolic localization of true malignant pathology so infection or inflammation in the pleural lining will not be mistaken for lung cancer.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.